PHAXIAM Therapeutics マネジメント

マネジメント基準チェック /24

PHAXIAM Therapeuticsの CEO はThibaut Fayetで、 Jun2023年に任命され、の在任期間は 1.42年です。の年間総報酬は€ 391.73Kで、 34.5%給与と65.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.055%を直接所有しており、その価値は€ 8.69K 。経営陣と取締役会の平均在任期間はそれぞれ1.4年と11.5年です。

主要情報

Thibaut Fayet

最高経営責任者

€391.7k

報酬総額

CEO給与比率	34.5%
CEO在任期間	1.4yrs
CEOの所有権	0.05%
経営陣の平均在職期間	1.4yrs
取締役会の平均在任期間	11.5yrs

経営陣の近況

Recent updates

CEO報酬分析

PHAXIAM Therapeutics の収益と比較して、Thibaut Fayet の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-€22m
Mar 31 2024	n/a	n/a	-€23m
Dec 31 2023	€392k	€135k	-€23m

報酬と市場: Thibautの総報酬 ($USD 414.52K ) は、 German市場 ($USD 475.63K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Thibautの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Thibaut Fayet (56 yo)

1.4yrs

在職期間

€391,725

報酬

Mr. Thibaut du Fayet serves as Chief Executive Officer at PHAXIAM Therapeutics S.A. since June 23, 2023. He served as Chief Operating Officer and served as Member of the Executive Board at Pherecydes Pharm...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Thibaut Fayet	Chief Executive Officer	1.4yrs	€391.73k	0.055% € 8.7k
Jérôme Bailly	Deputy CEO	4.8yrs	€262.41k	0.0038% € 599.6
Frédéric Mathat	Chief Financial Officer	less than a year	データなし	データなし
Cindy Fevre	Chief Scientific Officer	1.8yrs	データなし	データなし
Naomi Eichenbaum	Director Investor Relations	no data	データなし	データなし
Pascal Birman	Chief Medical Officer	1.4yrs	データなし	データなし
Philip Lorenzi	Consultant & Member of Scientific Board	no data	データなし	データなし
Eric Raymond	Consultant & Member of Scientific Board	no data	データなし	データなし
Bridget Bax	Consultant & Member of Scientific Board	no data	データなし	データなし
Arthur Frankel	Consultant & Member of Scientific Board	no data	データなし	データなし
Kurt Gunter	Consultant & Member of Scientific Board	no data	データなし	データなし

1.4yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: 2E40の経営陣は経験豊富とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Philip Lorenzi	Consultant & Member of Scientific Board	14.8yrs	データなし	データなし
Eric Raymond	Consultant & Member of Scientific Board	15.1yrs	データなし	データなし
Bridget Bax	Consultant & Member of Scientific Board	12.8yrs	データなし	データなし
Arthur Frankel	Consultant & Member of Scientific Board	12.8yrs	データなし	データなし
Kurt Gunter	Consultant & Member of Scientific Board	12.8yrs	データなし	データなし
Philippe Archinard	Independent Director	11.5yrs	€68.00k	0.010% € 1.6k
Gil Beyen	Vice Chairman	11.5yrs	€1.00m	0.0048% € 766.1
Hilde Windels	Independent Director	10.2yrs	€56.75k	データなし
Didier Hoch	Chairman of the Board	1.4yrs	€153.18k	データなし
Leila Nicolas	Representative Director	1.4yrs	€26.25k	データなし
Robert Sebbag	Independent Director	1.4yrs	€21.75k	データなし
Valerie Faillat	Independent Director	less than a year	データなし	データなし

11.5yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: 2E40の取締役会は経験豊富で経験豊富です ( 11.5年の平均在任期間)。

PHAXIAM Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Recent updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

New 90-day low: €6.90

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

New 90-day high: €8.81

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

New 90-day high: €7.70

New 90-day high: €6.33

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

New 90-day low: €4.30

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

New 90-day low: €4.82

New 90-day low - €6.02

New 90-day low - €6.62

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24